Inhibikase Therapeutics, Inc.
HealthcareNASDAQ:IKT · NASDAQ Capital Market
+$0.00 today
Vol 0.42M · Avg 1.06M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $49.6M |
| Short-term Investments | $120.8M |
| Other Current | $1.8M |
| Total Current Assets | $172.2M |
| Other Non-current | $1.2M |
| Total Non-current Assets | $1.2M |
| Total Assets | $173.3M |
Analysis
Selected assets total $173.3M for Latest. The largest visible component is Short-term Investments at $120.8M, about 69.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $139.2M +146.4% | $56.5M +516.4% | $9.2M +27.5% | $7.2M -82.4% | $40.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $39.5M -3.7% | $41.1M +904.5% | $4.1M -74.2% | $15.9M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 | $0 | $0 -100.0% | $39.9K -63.8% | $110.1K | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $1.3M +1165.5% | $106.3K -85.6% | $739.2K -33.9% | $1.1M +944.5% | $107.0K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $180.1M +82.9% | $98.5M +592.8% | $14.2M -41.7% | $24.4M -42.6% | $42.5M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $0 -100.0% | $148.5K -49.8% | $295.6K -47.7% | $565.2K | $0 | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $1.1M | $0 | $0 | $0 | $0 | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $1.1M +637.3% | $148.5K -49.8% | $295.6K -47.7% | $565.2K | $0 | -$15.3B | $14.8B | $11.3B |
| Total Assets | $181.2M +83.8% | $98.6M +579.7% | $14.5M -41.8% | $24.9M -41.3% | $42.5M | $13.3B | $11.9B | $10.6B |
| Account Payables | $1.2M +22.8% | $943.0K +45.8% | $646.8K -43.8% | $1.2M +5.6% | $1.1M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 -100.0% | $381.8K | $0 -100.0% | $248.9K | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $7.1M | $0 -100.0% | $635.5K | $0 | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $8.3M +122.3% | $3.7M +8.6% | $3.4M -7.0% | $3.7M -8.9% | $4.1M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $0 | $0 -100.0% | $90.1K -56.1% | $205.5K | $0 | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $8.3M +122.3% | $3.7M +5.8% | $3.5M -9.5% | $3.9M -3.8% | $4.1M | $14.7B | $3.7B | $9.6B |
| Common Stock | $131.7K +89.9% | $69.4K +1021.3% | $6.2K +46.4% | $4.2K -83.2% | $25.2K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$142.7M -51.1% | -$94.4M -41.1% | -$66.9M -39.7% | -$47.9M -60.5% | -$29.8M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $21.8K +158.5% | -$37.2K -4347.2% | $877 -99.2% | $104.7K | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 -100.0% | $777 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $172.9M +82.3% | $94.9M +764.2% | $11.0M -47.8% | $21.0M -45.2% | $38.4M | $9.1B | $7.7B | $3.3B |
| Total Debt | $0 -100.0% | $110.5K -82.2% | $622.0K +77.1% | $351.3K +41.1% | $248.9K | $724.2M | $410.6M | $399.4M |
| Net Debt | -$139.2M -146.9% | -$56.4M -559.9% | -$8.5M -25.0% | -$6.8M +83.1% | -$40.5M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
$353.16M
Turn Therapeutics Inc.
NASDAQ:TTRX
$180.07M
Surrozen, Inc.
NASDAQ:SRZN
$174.90M
Agenus Inc.
NASDAQ:AGEN
$137.42M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Entera Bio Ltd.
NASDAQ:ENTX
$60.63M
eXoZymes, Inc.
NASDAQ:EXOZ
$60.20M
Estrella Immunopharma, Inc.
ESLA
$45.62M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does IKT have?
Inhibikase Therapeutics, Inc. (IKT) reported $139.22M in cash and equivalents in fiscal 2025.
How much debt does IKT carry?
Inhibikase Therapeutics, Inc. (IKT) reported $0.00 of total debt, with net debt of -$139,220,208.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.